The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).
- Application Due Date(s): July 19, 2018; October 18, 2018; February 21, 2019; June 19, 2019; October 17, 2019; February 20, 2020; June 19, 2020; October 17, 2020; February 20, 2021
- AIDS Application Due Date(s): July 19, 2018; November 22, 2018; March 22, 2019; July 19, 2019; November 22, 2019; March 22, 2020; July 19, 2020; November 22, 2020; March 22, 2021
PAR-18-020 Expiration Date New Date March 23, 2019 per issuance of NOT-CA-16-037. (Original Expiration Date: March 23, 2018)
The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.